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`    Experimental design
1.   Sample size
Describe how sample size was determined. Due to the absolute novelty of PA-Nic, sample sizes were not determined prior to 
experimentation. We were guided by prior studies, cited in the Online Methods, for sample 
size expectations. 
2.   Data exclusions
Describe any data exclusions. Outlier data points were removed (rarely) via the ROUT method as described in the Online 
Methods.
3.   Replication
Describe the measures taken to verify the reproducibility 
of the experimental findings.
All experiments were independently replicated. Where samples were taken from animals, 
every reasonable effort was made to replicate findings in more than one animal. 
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
Where applicable, animals were randomly assigned to experimental groups via informal 
randomization. 
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
For chronic nicotine treatments, investigators performing recordings were blind to the 
treatment during the first ~50% of data collection to assure unbiased results.  
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present 
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
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`   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
Standard commercial software: MS Excel, GraphPad Prism, OriginLab, Clampfit, pClamp 10, 
MATLAB, PrairieView 5
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
`   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a third party.
All reagents and materials are available from the authors upon reasonable request.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
goat anti-ChAT (Millipore; cat# AB144P; clone n/a; lot 2843074) 
rabbit anti-DsRed (Clontech; cat# 632496; clone n/a; lot not available) 
anti-goat Alexa 488 (Invitrogen; cat# A11055; clone n/a; lot 1827671) 
anti-rabbit Alexa 647 (Invitrogen; cat# A31573; clone n/a; lot 1826679) 
Validation: 
Supplementary Figure 2d: anti-ChAT and anti-DsRed staining cross-validate each other since 
their signals should overlap in medial habenula of ChAT-Cre::Ai14 mice. 
Supplementary Figure 6c: anti-DsRed staining simply increased the signal from the 
endogenous tdTomato expressed specifically in GAD2 neurons in IPN. 
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. no cell lines were used in this study
b.  Describe the method of cell line authentication used. no cell lines were used in this study
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
no cell lines were used in this study
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
no cell lines were used in this study
`    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide all relevant details on animals and/or 
animal-derived materials used in the study.
species: mus musculus 
strain: C57BL/6 (Jackson Labs strain numbers 000664, 006410, 007914, 010802) 
sex: male and female 
age: 2 to 24 weeks old
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
this study did not involve human research participants
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